沃华医药(002107) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 259,375,844.83, representing a 2.73% increase compared to CNY 252,471,189.00 in the same period last year[3] - Net profit attributable to shareholders decreased by 47.11% to CNY 26,888,553.37 from CNY 50,842,995.37 year-on-year[3] - The total profit for the period was CNY 27,813,421.59, a decline of 53.39% compared to CNY 59,677,286.08 in the previous year[7] - Net profit for Q1 2022 was CNY 22,912,438.15, a decrease of 54.8% compared to CNY 50,722,586.35 in Q1 2021[17] - The total comprehensive income attributable to the parent company for Q1 2022 was CNY 26,888,553.37, compared to CNY 50,842,995.37 in the same period last year, reflecting a significant decrease[18] - The total comprehensive income for minority shareholders was CNY -3,976,115.22 in Q1 2022, compared to CNY -120,409.02 in the same period last year, indicating a worsening position for minority interests[18] Cash Flow and Liquidity - The net cash flow from operating activities fell by 41.78% to CNY 48,896,554.00, down from CNY 83,986,583.11 in the previous year[3] - The net cash flow from operating activities for Q1 2022 was CNY 48,896,554.00, down from CNY 83,986,583.11 in Q1 2021, indicating a decline of approximately 41.8%[21] - The company's cash and cash equivalents decreased to CNY 224,200,873.02 from CNY 326,843,819.45, representing a decline of 31.3%[12] - The cash and cash equivalents at the end of Q1 2022 were CNY 223,135,070.87, a decrease from CNY 510,777,278.46 at the end of Q1 2021, representing a decline of about 56.3%[22] - The company reported cash inflows from operating activities totaling CNY 278,874,679.77, compared to CNY 298,899,761.79 in the previous year, showing a decrease of approximately 6.7%[21] - The company reported a net increase in cash and cash equivalents of CNY -103,078,147.62 for Q1 2022, contrasting with an increase of CNY 21,916,406.15 in Q1 2021[22] Assets and Liabilities - Total assets decreased by 8.70% to CNY 1,060,131,756.47 from CNY 1,161,092,124.65 at the end of the previous year[3] - The total assets decreased to CNY 1,060,131,756.47 from CNY 1,161,092,124.65, a decline of 8.7%[14] - Total liabilities increased to CNY 258,030,733.23 from CNY 231,829,043.56, an increase of 11.3%[14] - Shareholders' equity attributable to the parent company dropped by 15.01% to CNY 697,530,553.44 from CNY 820,716,496.07[3] - The equity attributable to shareholders decreased to CNY 697,530,553.44 from CNY 820,716,496.07, a decrease of 15%[14] Operating Costs and Expenses - The company's operating costs increased by 30.13% to CNY 65,945,482.98, primarily due to rising raw material prices[7] - Total operating costs for Q1 2022 were CNY 231,011,940.52, up 20% from CNY 192,661,702.85 in Q1 2021[16] - Research and development expenses increased to CNY 14,040,887.58 from CNY 12,742,362.92, reflecting a growth of 10.2%[17] Earnings Per Share - The basic earnings per share decreased by 44.44% to CNY 0.05 from CNY 0.09 in the same period last year[3] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.05, down from CNY 0.09 in the same period last year, indicating a decline of approximately 44.4%[18]